U.S. markets closed
  • S&P 500

    4,207.27
    -2.97 (-0.07%)
     
  • Dow 30

    33,336.67
    +27.16 (+0.08%)
     
  • Nasdaq

    12,779.91
    -74.89 (-0.58%)
     
  • Russell 2000

    1,975.26
    +6.01 (+0.31%)
     
  • Crude Oil

    93.99
    +2.06 (+2.24%)
     
  • Gold

    1,805.50
    -8.20 (-0.45%)
     
  • Silver

    20.26
    -0.48 (-2.30%)
     
  • EUR/USD

    1.0324
    +0.0022 (+0.22%)
     
  • 10-Yr Bond

    2.8880
    +0.1020 (+3.66%)
     
  • GBP/USD

    1.2201
    -0.0017 (-0.14%)
     
  • USD/JPY

    132.9700
    +0.0970 (+0.07%)
     
  • BTC-USD

    24,181.77
    +347.79 (+1.46%)
     
  • CMC Crypto 200

    573.13
    -1.61 (-0.28%)
     
  • FTSE 100

    7,465.91
    -41.20 (-0.55%)
     
  • Nikkei 225

    27,819.33
    -180.63 (-0.65%)
     

UPDATE 2-Pfizer signs new $3.2 bln COVID vaccine deal with U.S. government

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

(Adds background, quote from U.S. official)

By Manas Mishra and Michael Erman

June 29 (Reuters) - Pfizer Inc and partner BioNTech SE said on Wednesday they signed a $3.2 billion deal with the U.S. government for 105 million doses of their COVID-19 vaccine, which could be delivered as soon as later this summer.

The deal includes supplies of a retooled Omicron-adapted vaccine, pending regulatory clearance, according to Pfizer.

Drugmakers have been developing vaccines to target the Omicron variant that became dominant last winter.

The average price per dose in the new deal is over $30, a more than 50% increase from the $19.50 per dose the U.S. government paid in its initial contract with Pfizer.

Some of the vaccine earmarked for adults included in the contract will be in single-dose vials, which are more expensive to manufacture but reduce waste of unused shots from open vials.

"We look forward to taking delivery of these new variant-specific vaccines and working with state and local health departments, pharmacies, healthcare providers, federally qualified health centers, and other partners to make them available in communities around the country this fall," U.S. Health and Human Services (HHS) official Dawn O’Connell said in a statement.

Advisers to the U.S. Food and Drug Administration on Tuesday recommended a change in the design of COVID-19 booster shots for this fall in order to combat more recently circulating variants of the coronavirus.

The U.S. government also has the option to purchase up to 195 million additional doses, bringing the total number of potential doses to 300 million, the companies said.

The new contract should boost 2022 vaccine sales for Pfizer and BioNTech, which share profits from the shots. Pfizer has forecast COVID-19 vaccine sales of $32 billion this year. Analysts, on average, have forecast 2022 sales of around $33.6 billion for the shots.

The U.S. government has distributed close to 450 million doses of the Pfizer/BioNTech vaccine in the United States since it was first authorized in December 2020, according to data from the U.S. Centers for Disease Control and Prevention. Over 350 million of those doses have been administered.

Because the Biden administration was unable to line up more COVID-19 funding from Congress earlier this month, it was forced to reallocate $10 billion of existing funding to pay for additional vaccines and treatments.

According to HHS, the money to pay for doses in this new contract comes from that funding. (Reporting by Manas Mishra in Bengaluru and Michael Erman in New York; Editing by Shounak Dasgupta and Bill Berkrot)